Gee, NWBO claims the naive OS data was confounded unrelated to the ECA.
From NWBO's own SEC filing: "The statistical analysis plan that we submitted to regulators for the Phase III trial embodies a different primary endpoint and secondary endpoint than did the original Protocol for the trial. Under the Protocol the primary endpoint was progression free survival, or PFS, and the secondary endpoint was overall survival, or OS. Both of these endpoints were confounded: the PFS endpoint by pseudo-progression, and the OS endpoint by the “crossover” provision in the trial design, which allowed all of the patients in the trial to cross over to DCVax-L treatment after tumor recurrence."
No claim that the ECA was related to the OS data from the trial.
News 
Market Data 
Discover 
